Theratechnologies to phase out preclinical oncology program as it looks for R&D partner

Preview

来源: FierceBiotech

While it's not clear how many jobs will be lost in the phase out, the move will reportedly cost the company about $625,000 in cash for severance payouts.

Theratechnologies is winding down its preclinical oncology research program in an effort to turn a profit and focus on its commercial business. The biotech will use what it has learned from the cancer work conducted so far to find an outside R&D collaborator.

The company's investment in a platform to treat multiple types of cancer by targeting the SORT1+ receptor “has generated important evidence on multiple peptide-drug conjugates with different payloads,” CEO Paul Lévesque said in a March 22 release. “Now that we have significantly advanced our preclinical program, we are well-positioned to leverage this wealth of data and insights to attract an oncology R&D partner.”

The move will cost the company about $625,000 in severance payouts and other expenses as well as $770,000 in non-cash charges. Six jobs will be cut as a result of the changes, but given that they'll happen over the coming months, no one will be impacted immediately, a spokesperson for Theratechnologies told Fierce Biotech.

The decision does not affect clinical progress for Theratechnologies’ lead oncology asset, a peptide-drug conjugate called sudocetaxel zendusortide. That therapy is currently being tested in a phase 1 trial for advanced ovarian cancer after overcoming an FDA hold over safety concerns.

Moving forward, Theratechnologies will continue to share findings generated prior to the preclinical wind down. The company plans to present two posters at the upcoming American Association for Cancer Research annual meeting in early April, including one with data on new peptide-drug conjugates.

Theratechnologies has two FDA-approved drugs on the market, both for HIV: An antiretroviral called Trogarzo for patients infected with HIV-1; and a growth hormone-releasing factor called Egrifta, which reduces the build-up of excess visceral abdominal fat that sometimes results from the condition. The company is also exploring the active ingredient of Egrifta, tesamorelin, as a potential treatment for metabolic dysfunction-associated steatohepatitis.

Editor's note: This article was updated March 25 with new details on impacted jobs from Theratechnologies.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。